Brief: Definium Therapeutics Says Study Of DT120 ODT Met Primary All Key Secondary Efficacy Endpoints
22/06/2026 12:00
BRIEF-Definium Therapeutics Says Study Of DT120 ODT Met Primary All Key Secondary Efficacy Endpoints June 22 (Reuters) - Definium Therapeutics Inc DFTX.O:
DEFINIUM THERAPEUTICS: POSITIVE TOPLINE RESULTS FROM PHASE 3 EMERGE STUDY OF DT120 ORALLY DISINTEGRATING TABLET (ODT) IN MAJOR DEPRESSIVE DISORDER
DEFINIUM THERAPEUTICS: STUDY OF DT120 ORALLY DISINTEGRATING TABLET MET PRIMARY ALL KEY SECONDARY EFFICACY ENDPOINTS
DEFINIUM THERAPEUTICS: DT120 ODT WAS GENERALLY WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS OR SUICIDALITY SIGNAL
((Reuters.Briefs@thomsonreuters.com;))